Eliapixant - Bayer
Alternative Names: BAY-181708; BAY-1817080Latest Information Update: 28 May 2024
At a glance
- Originator Bayer
- Class Amides; Analgesics; Antitussives; Fluorocarbons; Phenyl ethers; Pyrimidines; Small molecules; Thiazoles; Urologics
- Mechanism of Action Purinergic P2X3 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cough; Neuropathic pain; Overactive bladder
- Discontinued Endometriosis
Most Recent Events
- 28 May 2024 No recent reports of development identified for phase-I development in Cough(In volunteers) in China (PO, Tablet)
- 28 Sep 2023 No recent reports of development identified for phase-I development in Neuropathic-pain in USA (PO, Tablet)
- 28 Sep 2023 No recent reports of development identified for phase-I development in Overactive bladder in USA (PO, Tablet)